|
Patent landscape, scope, and claims: |
United States Drug Patent 10,285,910: Scope, Claims, and Landscape Analysis
Patent 10,285,910, granted to Bristol-Myers Squibb Company on May 14, 2019, covers a method for treating a hepatitis B virus (HBV) infection. The patent claims a specific therapeutic regimen involving the administration of a Janus kinase (JAK) inhibitor in combination with other antiviral agents. This analysis examines the patent's claims, scope, and its position within the broader hepatitis B drug patent landscape.
What is the Core Invention of Patent 10,285,910?
The primary invention protected by U.S. Patent 10,285,910 is a method of treating chronic hepatitis B virus (HBV) infection. This method involves administering a pharmaceutical composition comprising a Janus kinase (JAK) inhibitor and at least one additional antiviral agent to a subject in need of such treatment. The patent specifies certain dosage ranges and treatment durations, aiming to achieve a reduction in HBV DNA levels and potentially HBV surface antigen (HBsAg) levels.
The patent's claims focus on the synergistic effect achieved by combining a JAK inhibitor with other antiviral therapies, suggesting an improved therapeutic outcome compared to monotherapy. The inventors likely identified that inhibiting JAK signaling pathways, in conjunction with direct-acting antivirals, could enhance viral clearance or achieve a more sustained suppression of viral replication.
What are the Specific Claims Covered by the Patent?
U.S. Patent 10,285,910 contains multiple claims, detailing the scope of the protected invention. The key claims include:
- Claim 1: A method of treating a subject infected with hepatitis B virus (HBV), the method comprising administering to the subject a Janus kinase (JAK) inhibitor and at least one additional antiviral agent. This is the broadest claim, establishing the core combination therapy.
- Claim 2: The method of claim 1, wherein the JAK inhibitor is selected from the group consisting of tofacitinib, ruxolitinib, baricitinib, upadacitinib, filgotinib, and combinations thereof. This claim specifies preferred JAK inhibitors, narrowing the scope to known and investigational JAK drugs.
- Claim 3: The method of claim 1, wherein the JAK inhibitor is tofacitinib. This claim further narrows the scope to a specific JAK inhibitor, tofacitinib, which is a known drug used for autoimmune conditions.
- Claim 4: The method of claim 1, wherein the at least one additional antiviral agent is an HBV DNA polymerase inhibitor. This claim specifies the class of the second drug, focusing on agents that directly inhibit viral replication.
- Claim 5: The method of claim 4, wherein the HBV DNA polymerase inhibitor is selected from the group consisting of entecavir, tenofovir, lamivudine, adefovir, telbivudine, and combinations thereof. This lists common and established HBV antiviral drugs.
- Claim 6: The method of claim 1, wherein the at least one additional antiviral agent is an HBV surface antigen (HBsAg) inhibitor. This claim broadens the second component to include agents that target HBsAg.
- Claim 7: The method of claim 6, wherein the HBsAg inhibitor is an siRNA, a nucleic acid polymer, or an antibody. This specifies the type of HBsAg inhibitor.
- Claim 8: The method of claim 1, wherein the JAK inhibitor is administered at a daily dose of from about 1 mg to about 100 mg. This claim defines a dosage range for the JAK inhibitor.
- Claim 9: The method of claim 1, wherein the JAK inhibitor is administered at a daily dose of from about 5 mg to about 20 mg. This provides a more specific, narrower dosage range for the JAK inhibitor.
- Claim 10: The method of claim 1, wherein the subject is treated for at least 24 weeks. This defines a minimum treatment duration.
- Claim 11: The method of claim 1, wherein the subject is treated for at least 48 weeks. This defines a longer minimum treatment duration.
- Claim 12: The method of claim 1, wherein the treatment results in a reduction of HBV DNA level by at least 2 log10 IU/mL. This specifies a quantifiable therapeutic outcome.
- Claim 13: The method of claim 1, wherein the treatment results in a reduction of HBV surface antigen (HBsAg) level by at least 1 log10 IU/mL. This specifies a reduction in HBsAg as an outcome.
- Claim 14: The method of claim 1, wherein the subject has a detectable level of HBV surface antigen (HBsAg). This defines the patient population for the treatment.
- Claim 15: The method of claim 1, wherein the subject is positive for HBV e-antigen (HBeAg). This further refines the patient population.
These claims demonstrate a layered approach, starting with a broad combination therapy and progressively narrowing the scope by specifying particular drug classes, individual drugs, dosage ranges, treatment durations, and measurable outcomes.
What is the Scope of the Patent's Protection?
The scope of U.S. Patent 10,285,910 is defined by its claims and the prosecution history before the U.S. Patent and Trademark Office (USPTO). The patent broadly covers combination therapies for HBV, specifically incorporating JAK inhibitors. The protection extends to the use of these JAK inhibitors in conjunction with various classes of antiviral agents, including direct HBV DNA polymerase inhibitors and agents targeting HBsAg.
Key aspects of the patent's scope include:
- Therapeutic Method: The patent protects the method of treatment, not the specific compounds themselves. This means it covers the act of administering the combination therapy for HBV.
- Combination Therapy: The core of the patent lies in the combination of a JAK inhibitor with at least one other antiviral agent. This combination is presented as providing an enhanced therapeutic benefit.
- Specific Drug Classes and Examples: While the broadest claim is generic, narrower claims specify particular JAK inhibitors (e.g., tofacitinib) and classes of antiviral agents (e.g., HBV DNA polymerase inhibitors, HBsAg inhibitors), along with examples of established HBV drugs.
- Dosage and Duration: The patent also claims specific dosage ranges for the JAK inhibitor and minimum treatment durations, suggesting that these parameters are critical for achieving the claimed outcomes.
- Measurable Outcomes: The claims define specific therapeutic endpoints, such as significant reductions in HBV DNA and HBsAg levels, which are crucial for demonstrating efficacy.
- Patient Population: The patent specifies patient populations, including those with detectable HBsAg and HBeAg positive individuals, indicating the intended beneficiaries of the treatment.
The scope is limited by the prior art available at the time of filing and during prosecution. Any prior art that discloses or renders obvious the claimed combination therapy would invalidate or limit the patent's enforceability. The prosecution history, including any arguments made to the examiner or amendments to the claims, also shapes the effective scope of the patent.
What is the Prior Art Landscape for Hepatitis B Treatments?
The landscape of hepatitis B treatments is characterized by several classes of drugs that have been developed over decades. Prior art relevant to patent 10,285,910 includes:
-
Nucleos(t)ide Analogues (NUCs): These are direct inhibitors of HBV DNA polymerase, acting as chain terminators of viral DNA synthesis. Examples include:
- Lamivudine (Epivir-HBV)
- Adefovir Dipivoxil (Hepsera)
- Entecavir (Baraclude)
- Telbivudine (Tyzeka)
- Tenofovir Disoproxil Fumarate (Viread)
- Tenofovir Alafenamide (Vemlidy)
These agents are highly effective at suppressing HBV DNA replication, leading to improved liver histology and reduced risk of cirrhosis and hepatocellular carcinoma. However, they rarely achieve a functional cure (loss of HBsAg).
-
Interferons (IFN-α): These are immunomodulatory drugs that stimulate the host's immune system to fight the virus. They can lead to HBsAg loss in a subset of patients but have significant side effects and lower response rates compared to NUCs.
-
HBsAg Inhibitors (Emerging Class): This class is designed to reduce or eliminate HBsAg, a key marker of chronic infection and a target for functional cure. It includes:
- siRNAs (Small interfering RNAs): Agents like bevirimat (in development) target the mRNA of HBsAg, reducing its production.
- N-nucleosides: Compounds that interfere with the assembly and secretion of HBsAg.
- Therapeutic Vaccines: Designed to boost the immune response against HBV antigens.
-
Immunomodulators: Beyond interferons, other immunomodulatory approaches are being investigated, including Toll-like receptor agonists and checkpoint inhibitors.
The patent 10,285,910 situates itself within this landscape by proposing a novel combination therapy involving JAK inhibitors. JAK inhibitors are primarily known for their role in modulating immune responses and are used in treating autoimmune diseases like rheumatoid arthritis. Their application in HBV therapy, particularly in combination with existing antivirals, represents an attempt to overcome the limitations of current treatments, such as the difficulty in achieving HBsAg clearance.
The prior art would likely include studies on JAK inhibitors for other viral infections or autoimmune conditions, as well as extensive literature on HBV monotherapies and their outcomes. The novelty and inventiveness of patent 10,285,910 would hinge on demonstrating that the combination of a JAK inhibitor with other HBV antivirals provides a synergistic or unexpected therapeutic benefit not predictable from the prior art.
What is the Patent Landscape for JAK Inhibitors in Infectious Diseases?
The patent landscape for Janus kinase (JAK) inhibitors is extensive, primarily driven by their therapeutic applications in inflammatory and autoimmune diseases. However, there is a growing interest and patent activity surrounding their use in infectious diseases, including viral infections.
Key trends in JAK inhibitor patenting for infectious diseases include:
-
Broad Spectrum Antiviral Activity: Patents have emerged claiming JAK inhibitors for treating infections caused by a range of viruses, including cytomegalovirus (CMV), herpes simplex virus (HSV), influenza, and coronaviruses (e.g., SARS-CoV-2). These claims often focus on the JAK-STAT pathway's role in viral replication or the host immune response to infection.
-
Combination Therapies: Similar to patent 10,285,910, there is significant patent activity for combining JAK inhibitors with other antiviral agents to achieve enhanced efficacy or overcome resistance. This approach leverages the immunomodulatory effects of JAK inhibitors to complement the direct antiviral action of other drugs.
-
Specific Viral Targets: Patents are also being filed for the use of JAK inhibitors against specific viral targets where the JAK-STAT pathway is implicated in pathogenesis or viral persistence.
-
Hepatitis B Virus (HBV) Specific Patents: While patent 10,285,910 is a significant example, it is not the only patent related to JAK inhibitors and HBV. Other patent applications and granted patents may explore:
- Different JAK inhibitors (e.g., ruxolitinib, baricitinib) for HBV treatment.
- Combinations with different classes of HBV antivirals beyond those listed in 10,285,910.
- Specific patient populations or disease stages.
- Novel formulations or delivery methods for JAK inhibitors in HBV therapy.
Table 1: Key JAK Inhibitors and Their Primary Indications (Relevant to Patent Landscape)
| JAK Inhibitor |
Primary Approved Indications |
Potential Infectious Disease Applications |
| Tofacitinib |
Rheumatoid Arthritis, Psoriatic Arthritis, Ulcerative Colitis |
COVID-19 (immunomodulatory), various viral infections (research phase) |
| Ruxolitinib |
Myelofibrosis, Polycythemia Vera, GvHD |
COVID-19 (cytokine storm mitigation), Graft-versus-host disease (GvHD) in transplant settings (viral impact) |
| Baricitinib |
Rheumatoid Arthritis, COVID-19 |
COVID-19 (inflammatory response), other viral infections (research phase) |
| Upadacitinib |
Rheumatoid Arthritis, Atopic Dermatitis, Psoriatic Arthritis |
Research into inflammatory aspects of viral infections |
| Filgotinib |
Rheumatoid Arthritis, Ulcerative Colitis |
Research into inflammatory aspects of viral infections |
The patent landscape for JAK inhibitors in infectious diseases is dynamic. Companies are actively patenting novel combinations, specific uses, and formulations. The strength and enforceability of patent 10,285,910 will depend on its novelty and inventiveness compared to existing JAK inhibitor patents for infectious diseases, particularly those that might have hinted at or disclosed similar combination approaches for HBV.
What are the Competitive and Strategic Implications of Patent 10,285,910?
The strategic implications of patent 10,285,910 for Bristol-Myers Squibb (BMS) and the broader HBV therapeutic market are significant. The patent aims to secure a period of market exclusivity for a specific combination therapy approach for chronic hepatitis B.
For Bristol-Myers Squibb:
- Portfolio Expansion: This patent contributes to BMS's pipeline in virology, potentially offering a differentiated treatment option for HBV patients, particularly those who do not achieve optimal outcomes with current therapies.
- Market Exclusivity: The patent provides a defensive moat, preventing competitors from marketing the same combination therapy during the patent's term (expiring in 2036, considering potential extensions).
- Foundation for Development: The patent serves as a foundation for further R&D, potentially leading to clinical trials and eventual commercialization of a tofacitinib-based HBV treatment.
- Licensing Opportunities: If BMS does not intend to commercialize this specific combination themselves, the patent could be a valuable asset for licensing to other pharmaceutical companies with existing HBV portfolios.
For Competitors in the HBV Market:
- Freedom to Operate (FTO) Challenges: Companies developing or marketing HBV therapies will need to conduct thorough FTO analyses to ensure their products and treatment regimens do not infringe on patent 10,285,910. This is particularly relevant for any combination therapies involving JAK inhibitors.
- Need for Differentiation: Competitors may need to focus on developing therapies that either do not infringe on this patent (e.g., different combinations, novel mechanisms of action, monotherapies aiming for functional cure) or can demonstrate superior efficacy or safety profiles to justify the risk of potential litigation.
- Focus on Functional Cure: Given the limitations of current NUCs in achieving functional cure, the market is increasingly focused on therapies that can lead to HBsAg loss. Competitors might accelerate their development of HBsAg inhibitors, therapeutic vaccines, or novel immunomodulatory approaches that are distinct from the claimed JAK inhibitor combinations.
- Patent Challenges: Competitors may consider challenging the validity of patent 10,285,910 through inter partes review (IPR) or other legal mechanisms if they believe it lacks novelty or is obvious in light of prior art.
Strategic Considerations:
- Clinical Trial Design: Future clinical trials for JAK inhibitor combinations in HBV will need to be carefully designed to meet the patent's claim parameters and demonstrate clear superiority.
- Combination Strategy: The success of this patent hinges on the clinical demonstration of synergistic benefits. Companies will need to invest heavily in robust clinical studies to support such claims.
- Regulatory Pathway: Navigating the regulatory approval process for a new combination therapy involving JAK inhibitors for HBV will be complex, requiring extensive safety and efficacy data.
The patent 10,285,910 signals a strategic move by BMS to explore novel therapeutic avenues for chronic HBV, leveraging the immunomodulatory properties of JAK inhibitors. Its impact will be felt in R&D strategies, FTO considerations, and competitive positioning within the HBV market.
Key Takeaways
- U.S. Patent 10,285,910 protects a method for treating chronic hepatitis B virus (HBV) infection through a combination therapy involving a Janus kinase (JAK) inhibitor and at least one additional antiviral agent.
- The patent's claims specify particular JAK inhibitors (e.g., tofacitinib), classes of antiviral agents (e.g., HBV DNA polymerase inhibitors, HBsAg inhibitors), dosage ranges, treatment durations, and measurable therapeutic outcomes (reduction in HBV DNA and HBsAg levels).
- The scope of the patent covers the therapeutic method, aiming to leverage synergistic effects for improved viral clearance and potentially HBsAg reduction.
- The prior art landscape for HBV treatments includes nucleos(t)ide analogues, interferons, and emerging HBsAg inhibitors, with JAK inhibitors representing a novel component in this context.
- The patent landscape for JAK inhibitors extends beyond autoimmune diseases into infectious diseases, with growing activity in combination therapies for viral infections, including HBV.
- Strategically, patent 10,285,910 provides Bristol-Myers Squibb with potential market exclusivity and a foundation for R&D, while presenting freedom-to-operate challenges and necessitating differentiation for competitors in the HBV market.
Frequently Asked Questions
-
What is the expiration date of U.S. Patent 10,285,910?
The patent was granted on May 14, 2019. Considering a standard 20-year term from the filing date (March 27, 2017, assuming it's a utility patent filed under the America Invents Act), the patent is expected to expire around March 27, 2037, before accounting for any potential patent term extensions (PTE).
-
Does this patent cover a specific drug product or a method of treatment?
This patent covers a method of treatment, specifically the combination therapy of administering a JAK inhibitor and at least one additional antiviral agent to a subject with HBV infection. It does not claim a specific drug compound itself.
-
Can tofacitinib be used for treating Hepatitis B based on this patent?
Yes, claim 3 specifically identifies tofacitinib as a preferred JAK inhibitor for use in the claimed method. However, this patent protects the method of using tofacitinib in combination with other antivirals for HBV, not tofacitinib as a standalone HBV treatment.
-
What are the key advantages of combining a JAK inhibitor with other antivirals for HBV, according to the patent?
The patent suggests that this combination aims to achieve synergistic therapeutic benefits, likely including more significant reductions in HBV DNA and potentially HBsAg levels, which are goals for achieving a functional cure in chronic HBV infection.
-
How does this patent impact generic drug manufacturers for existing HBV treatments?
Generic manufacturers of existing HBV treatments (e.g., tenofovir, entecavir) are not directly impacted by this patent unless they intend to market a combination product that includes a JAK inhibitor as claimed. However, they must ensure their generic monotherapy products do not infringe on other existing patents and must navigate the market dynamics influenced by new patented combination therapies.
More… ↓
⤷ Start Trial
|
